These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 2951178)
1. A comparison of premixed with patient-mixed insulins. Corcoran JS; Yudkin JS Diabet Med; 1986 May; 3(3):246-9. PubMed ID: 2951178 [TBL] [Abstract][Full Text] [Related]
2. Improvement in morning hyperglycaemia with basal human ultratard and prandial human actrapid insulin--a comparison of multiple injection regimens. Davies RR; McEwen J; Moreland TA; Durnin C; Newton RW Diabet Med; 1988 Oct; 5(7):671-5. PubMed ID: 2975553 [TBL] [Abstract][Full Text] [Related]
3. The clinical effects of mixing short- and intermediate-acting insulins in the treatment of non-insulin-dependent diabetes. Best JD; Ley CJ; Strauss BJ; Alford FP; Aitken PM Med J Aust; 1987 Jun; 146(12):621-3, 627. PubMed ID: 3306298 [TBL] [Abstract][Full Text] [Related]
4. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia. Francis AJ; Hanning I; Alberti KG Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523 [TBL] [Abstract][Full Text] [Related]
5. Comparison of two twice-daily insulin regimens: ultralente/soluble and soluble/isophane. Ward GM; Simpson RW; Ward EA; Turner RC Diabetologia; 1981 Oct; 21(4):383-6. PubMed ID: 7026334 [TBL] [Abstract][Full Text] [Related]
6. A within patient cross over trial of 4 insulin regimens in antibody-negative, C-peptide negative patients. Oswald GA; Yudkin JS Diabetes Res; 1987 Feb; 4(2):85-9. PubMed ID: 3555956 [TBL] [Abstract][Full Text] [Related]
7. A comparison of human ultralente- and lente-based twice-daily injection regimens. Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130 [TBL] [Abstract][Full Text] [Related]
8. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study. Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500 [TBL] [Abstract][Full Text] [Related]
9. Need stable diabetics mix their insulins? Roland JM Diabet Med; 1984 May; 1(1):51-3. PubMed ID: 6242778 [TBL] [Abstract][Full Text] [Related]
10. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins. Heine RJ; Bilo HJ; Fonk T; van der Veen EA; van der Meer J Diabetologia; 1984 Dec; 27(6):558-62. PubMed ID: 6397384 [TBL] [Abstract][Full Text] [Related]
11. The contribution of intermediate-acting insulin preparations to daytime insulin treatment. Robert JJ; Chevenne D; Debray M Diabet Med; 1989 Aug; 6(6):531-6. PubMed ID: 2527136 [TBL] [Abstract][Full Text] [Related]
12. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics. Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Torjesen P; Try K Scand J Clin Lab Invest; 1989 Nov; 49(7):653-9. PubMed ID: 2692136 [TBL] [Abstract][Full Text] [Related]
13. Miscibility of human semisynthetic regular and lente insulin and human biosynthetic regular and NPH insulin. Olsson PO; Hans A; Henning VS Diabetes Care; 1987; 10(4):473-7. PubMed ID: 3304898 [TBL] [Abstract][Full Text] [Related]
14. Dose-dependent subcutaneous absorption of porcine, bovine and human NPH insulins. Hildebrandt P; Birch K; Sestoft L; Vølund A Acta Med Scand; 1984; 215(1):69-73. PubMed ID: 6364700 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018 [TBL] [Abstract][Full Text] [Related]
16. A comparison of biosynthetic human insulin with porcine insulin in the blood glucose control of diabetic pregnancy. Leiper JM; Paterson KR; Lunan CB; MacCuish AC Diabet Med; 1986 Jan; 3(1):49-51. PubMed ID: 2951136 [TBL] [Abstract][Full Text] [Related]
17. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Rosenstock J; Park G; Zimmerman J; Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511 [TBL] [Abstract][Full Text] [Related]
18. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810 [TBL] [Abstract][Full Text] [Related]
19. Do high fasting glucose levels suggest nocturnal hypoglycaemia? The Somogyi effect-more fiction than fact? Choudhary P; Davies C; Emery CJ; Heller SR Diabet Med; 2013 Aug; 30(8):914-7. PubMed ID: 23672623 [TBL] [Abstract][Full Text] [Related]
20. Ultralente based insulin regimens--clinical applications, advantages and disadvantages. Turner RC; Phillips MA; Ward EA Acta Med Scand Suppl; 1983; 671():75-86. PubMed ID: 6349269 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]